Suppl Fig S3 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Western blot showing additive effect of combined inhibition of EGFR and MAPK signaling
Fields of Study & Subjects
Colorectal Cancer Treatments and Studies
Melanoma and MAPK Pathways
Lung Cancer Treatments and Mutations
Publication details
- Publication date
- 2 April 2026
- Language
- EN